Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

87.39 -0.68 (-0.78%)
Streaming Delayed Price Updated: 3:54 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 7
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 2-6, 2024. 
Via Talk Markets
Topics Stocks / Equities
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
How Is The Market Feeling About Glaukos?
 
Via Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
Analyst Scoreboard: 5 Ratings For Glaukos
 
Via Benzinga
How Is The Market Feeling About Glaukos?
 
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Glaukos
 
Via Benzinga
Navigating 11 Analyst Ratings For Glaukos
 
Via Benzinga
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds. 
Via Benzinga
Glaukos Announces Third Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
From Glaukos Corporation
Via Business Wire
Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
 
Via Benzinga
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
10 Analysts Have This To Say About Glaukos
 
Via Benzinga
Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
 
Via Benzinga
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Glaukos Announces Second Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
7 Leading MedTech Stocks for Next-Gen Health Solutions
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar. 
Via InvestorPlace
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31
From Glaukos Corporation
Via Business Wire
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst
Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%. 
Via Benzinga
Topics Earnings
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.